Fostering healthy cognitive ageing in people living with HIV
- PMID: 39615509
- DOI: 10.1016/S2352-3018(24)00248-0
Fostering healthy cognitive ageing in people living with HIV
Abstract
Prevalence and incidence of HIV among people aged 50 years and older continue to rise worldwide, generating increasing awareness among care providers, scientists, and the HIV community about the importance of brain health in older adults with HIV. Many age-related factors that adversely affect brain health can occur earlier and more often among people with HIV, including epigenetic ageing, chronic medical conditions (eg, cardiovascular disease), and age-related syndromes (eg, frailty). Extensive dialogue between HIV community leaders, health-care providers, and scientists has led to the development of a multidimensional response strategy to protect and enhance brain health in people ageing with HIV that spans across public health, clinical spaces, and research spaces. This response strategy was informed by integrated ageing care frameworks and is centred on prevention, early detection, and management of brain health issues associated with HIV (eg, neurocognitive disorders), with specific considerations for low-resource or middle-resource countries. A collaborative, international, and data-informed update of the diagnostic criteria for HIV-associated neurocognitive disorders is a cornerstone of the proposed response strategy. The proposed response strategy includes a dynamic, international, online knowledge hub that will provide a crucial community resource for emerging evidence on the brain health of people ageing with HIV.
Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.
Conflict of interest statement
Declaration of interests BJB reports royalties from Oxford University Press and Cambridge University Press; honoraria for presentations sponsored by the Neurological Association of South Africa, Jansen, and Biogen; patents (monoclonal antibody for quinolinic acid as part of test kit for monitoring multiple sclerosis severity and progression [PCT/IB2013/055902; patent office Australia], 2010; method and prognostic kit for monitoring multiple sclerosis [WO/2015/008111], 2013; and automatic fall and seizure detector [application number 2016904045 IP Australia Batch Reference SPBI-0001069085 by My Medic Watch]); a position as Chairperson of the data monitoring and ethics committee for the Lighthouse 2 phase 3 study of the antiretroviral Triumeq in Amyotrophic Lateral Sclerosis (King's College London, UK, and Tysabri Advisory Board Australia); and a role as a past President of the International Society for Neurovirology (2019–23). JV reports honoraria for presentations and research grants in trials sponsored by Merck, Janssen Cilag, ViiV Healthcare, and Gilead Sciences. KG reports support from the Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (ACGT) Network (funded by the US National Institutes of Health) as Protocol Director for ACTG trial A5402, Cipla, and Dr Reddy's Laboratories. All other authors declare no competing interests.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical